一项随机临床试验,评估用于改善糖尿病前期成人血糖控制的数字治疗药物 (TH-001)
Ramazan Cakmak1, İlker Tosun2, Hasan Avcu2
1Department of Endocrinology, Istinye University, İstanbul, Turkey.
Digital health
|September 15, 2025
概括
一种数字治疗药物TH-001显著降低了糖尿病前期成人血红蛋白A1c (HbA1c) 和体重. 高用户参与度与改善的HbA1c相关,显示了其克服传统程序障碍的潜力.
科学领域:
- 对代谢健康的数字疗法进行临床研究.
- 糖尿病预防和管理策略.
- 针对糖尿病前期的公共卫生倡议.
背景情况:
- 糖尿病前期影响着全球大量人口,增加了2型糖尿病的风险.
- 传统的糖尿病预防计划面临着可扩展性和可访问性挑战.
- 数字疗法 (DTx) 为糖尿病前期管理提供了一个有希望的,可扩展的解决方案.
研究的目的:
- 为了评估TH-001的疗效和安全性,数字治疗,在降低HbA1c在糖尿病前期的成年人.
- 评估TH-001在90天干预期间对血糖指标和人类测量指标的影响.
- 探索用户参与TH-001和临床结果之间的关系.
主要方法:
- 一个随机的,开放的,受控的,并行组临床试验,涉及68名糖尿病前期的成年人.
- 参与者被分配到标准护理或标准护理以及TH-001干预.
- 主要结局包括HbA1c,禁食葡萄糖,2小时后的葡萄糖和胰岛素水平;次要结局包括人体测量和用户参与.
主要成果:
- 与标准护理相比,TH-001干预导致HbA1c水平 (平均差异-0.22%,p=0.023) 和体重 (-2.53公斤,p<0.001) 在统计学上显著降低.
- 对于空腹葡萄糖和胰岛素水平,观察到积极的趋势,尽管在统计学上并不显著.
- 使用TH-001的高用户参与度与HbA1c降低有很强的相关性 (r=0.95,p<0.001).
结论:
- 在患有糖尿病前期的成年人中,TH-001在改善HbA1c和降低体重方面表现出显著的有效性.
- 持续的用户参与是数字治疗在预防糖尿病的有效性的一个关键因素.
- TH-001显示出克服与糖尿病预防计划相关的传统障碍的潜力,需要进一步的长期研究.
更多相关视频
相关概念视频
Diabetes: Management and Pharmacotherapy
868
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
868
Clinical Trials
10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones
587
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
587
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Insulin: Dosing Regimen and Adverse Effects
689
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
689


